BRAIN TUMOR TREATMENT

To schedule an appointment 1-800-CEDARS-1 (1-800-233-2771) OR EMAIL US HERE

print button

Primary and Recurrent Malignant Glioma (Tumor Lysate Vaccine Immunotherapy)

A PHASE I TRIAL OF SURGICAL RESECTION FOLLOWED BY VACCINATION WITH DENDRITIC CELLS PULSED WITH TUMOR LYSATE WITH IMIQUIMOD (IRB #19814)


A Phase I Trial of Surgical Resection Followed by Vaccination with Dendritic Cells Pulsed with Tumor Lysate with Imiquimod for Patients with Malignant Glioma (#19814)

  • Patients must have histopathological diagnosis of newly diagnosed or recurrent malignant glioma (GBM, AA, AOA, AO)
  • Patients must have a gross total or near gross total resection at CSMC 

This study is being done to determine whether vaccinations with a patient’s own dendritic cells that have been pulsed with tumor lysate can activate an antitumor response. Tumor cells are taken at the time of surgery, frozen and combined with the subject’s dendritic cells to from the vaccine.  These cells are then re-injected intradermally back into patient every 2 weeks for 3 doses. Imiquimod is an FDA approved cream that is an immune response modifier.

Surasak Phuphanich, MD, FAAN
Director, Neuro-oncology Program
phuphanich@cshs.orG
Phone: (310) 423-8100

Christy Davis, RN
christy.davis2@cshs.org
Phone: (310) 423-0022

© 2013 All rights reserved. Cedars-Sinai
8-X